SFX-01 featured in Nature Reviews Drug Discovery

 RNS REACH

Evgen Pharma plc

 ("Evgen" or "the Company")

 Lead product SFX-01 featured in Nature Reviews Drug Discovery

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that both Evgen and its lead product, SFX-01, are considered in a recently published paper in Nature Reviews Drug Discovery entitled 'Therapeutic targeting of the Nrf2 and KEAP1 partnership in chronic diseases'.

The paper, in which Evgen CEO Stephen Franklin is a co-author, is a comprehensive and authoritative review of the importance of the Nrf2 pathway in the maintenance of redox, metabolic and protein homeostasis, as well as the regulation of inflammation. Evidence is presented showing that Nrf2 activation provides cytoprotection against numerous pathologies including chronic diseases of the lung and liver; autoimmune, neurodegenerative and metabolic disorders; and cancer initiation.

The paper also reviews the status of Nrf2 modulators in clinical development of which SFX-01 is one of the more advanced.

The abstract of the paper can be viewed at https://www.ncbi.nlm.nih.gov/pubmed/30610225

The full paper will be available to those with an academic institute affiliation or can be purchased or rented at  https://www.nature.com/articles/s41573-018-0008-x

Dr Stephen Franklin, CEO of Evgen, commented:

''I am delighted that both the significance of the Nrf2 pathway in many chronic diseases, and equally the promise of Nrf2 activators including SFX-01, in treating these diseases has been emphasised in such a prestigious journal thus further endorsing Evgen's approach and pipeline.''

Enquiries:

Notes for editors:

About Evgen Pharma plc

Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/